GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: example 10 [WO2021242505] | HT-6184 | HT6184
Compound class:
Synthetic organic
Comment: The chemical structure for ofirnoflast was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a serine/ threonine-protein kinase NIMA related kinase 7 (NEK7) inhibitor with anti-inflammatory potential. It is one of the examples claimed in Halia Therapeutics' patent WO2021242505A1 [1]. NEK7 inhibitors are being explored for anti-inflammatory activity that is mediated via inhibition of NLRP3 inflammasome activation thereby leading to reduced production of the pro-inflammatory cytokines IL-1β and IL-18. Halia Therapeutics have several NEK7 inhibitors in their development pipeline, the most advanced of which is HT-6184 (phase 2 for inflammatory pain). The only confirmation that aligns ofirnoflast with the company code HT-6184 that we have found is with the use of ofirnoflast as 'other names' in clinical trial records (March 2026). This 2026 article that describes ofirnoflast's binding mode, and in vitro and in vivo characteristics does not disclose its chemical structure or synonym [2]. It does however reveal that ofirnoflast engages an allosteric site adjacent to the enzymes ATP-binding pocket.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| Small molecule inhibitors that directly target NEK7 to downregulate the inflammatory response modulated by the NLRP3 inflammasome (to abolish production of the pro-inflammatory cytokines IL-1β and IL-18) offer potential to treat inflammation-mediated pathology, either as therapeutics or prophylactics. Ofirnoflast binding to NEK7 disrupts its scaffolding function in NLRP3 inflammasome assembly, and validates NEK7 as a druggable checkpoint for NLRP3 inflammasome control with utility for the treatment of inflammation driven by inflammasome hyper-activation. |